447 related articles for article (PubMed ID: 27188329)
21. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
22. Outcome of rheumatoid arthritis following adjunct statin therapy.
Das S; Mohanty M; Padhan P
Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A
Kato M; Kaneko Y; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Yokota I; Atsumi T; Takeuchi T
Mod Rheumatol; 2020 May; 30(3):442-449. PubMed ID: 31106666
[No Abstract] [Full Text] [Related]
24. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
25. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
[TBL] [Abstract][Full Text] [Related]
26. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.
Charles-Schoeman C; Wang X; Lee YY; Shahbazian A; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; O'Dell J; Bathon JM; Paulus H; Bridges SL; Curtis JR
Arthritis Rheumatol; 2016 Mar; 68(3):577-86. PubMed ID: 26606398
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.
Plein S; Erhayiem B; Fent G; Horton S; Dumitru RB; Andrews J; Greenwood JP; Emery P; Hensor EM; Baxter P; Pavitt S; Buch MH
Ann Rheum Dis; 2020 Nov; 79(11):1414-1422. PubMed ID: 32859608
[TBL] [Abstract][Full Text] [Related]
28. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Charles-Schoeman C; Yin Lee Y; Shahbazian A; Wang X; Elashoff D; Curtis JR; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; Paulus H; O'Dell J; Bathon J; Louis Bridges S; Reddy ST
Arthritis Rheumatol; 2017 Jan; 69(1):46-57. PubMed ID: 27483410
[TBL] [Abstract][Full Text] [Related]
29. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
[TBL] [Abstract][Full Text] [Related]
30. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
31. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
32. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
[TBL] [Abstract][Full Text] [Related]
33. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
35. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
36. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
[TBL] [Abstract][Full Text] [Related]
37. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T;
Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
[TBL] [Abstract][Full Text] [Related]
38. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G
Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937
[TBL] [Abstract][Full Text] [Related]
39. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
[TBL] [Abstract][Full Text] [Related]
40. A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid Arthritis.
Ciregia F; Nys G; Cobraiville G; Badot V; Di Romana S; Sidiras P; Sokolova T; Durez P; Fillet M; Malaise MG; de Seny D
Front Immunol; 2021; 12():638814. PubMed ID: 34489924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
